Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4
- PMID: 1373203
- PMCID: PMC241075
- DOI: 10.1128/JVI.66.5.3125-3130.1992
Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4
Abstract
Neutralization of human immunodeficiency virus type 1 (HIV-1) infection with soluble CD4 (sCD4) can be achieved over a broad range of concentrations for different virus strains. Laboratory virus strains passaged in transformed T-cell lines are typically sensitive to sCD4 neutralization, whereas primary virus isolates require over 100-fold-higher sCD4 concentrations. Using recombinant viruses generated from a laboratory strain, HIV-1NL4-3, and a primary macrophagetropic strain, HIV-1JR-FL, we mapped a region of gp120 important for determining sensitivity to sCD4 neutralization. This same region has previously been defined as important for macrophage and transformed T-cell line tropism and includes the V3 neutralization domain but does not include regions of gp120 that have been shown to be most important for CD4 binding.
Similar articles
-
Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.J Virol. 1994 Aug;68(8):5264-9. doi: 10.1128/JVI.68.8.5264-5269.1994. J Virol. 1994. PMID: 8035523 Free PMC article.
-
Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.J Virol. 1995 Jan;69(1):523-7. doi: 10.1128/JVI.69.1.523-527.1995. J Virol. 1995. PMID: 7983749 Free PMC article.
-
Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.J Virol. 1992 Jan;66(1):235-43. doi: 10.1128/JVI.66.1.235-243.1992. J Virol. 1992. PMID: 1727487 Free PMC article.
-
Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.J Virol. 1993 Oct;67(10):6179-91. doi: 10.1128/JVI.67.10.6179-6191.1993. J Virol. 1993. PMID: 7690420 Free PMC article.
-
CD4 activation of HIV fusion.Int J Cell Cloning. 1992 Nov;10(6):323-32. doi: 10.1002/stem.5530100603. Int J Cell Cloning. 1992. PMID: 1281202 Review.
Cited by
-
Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cells.J Virol. 2011 May;85(9):4409-20. doi: 10.1128/JVI.02244-10. Epub 2011 Feb 16. J Virol. 2011. PMID: 21325401 Free PMC article.
-
Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions.J Virol. 1996 May;70(5):2825-31. doi: 10.1128/JVI.70.5.2825-2831.1996. J Virol. 1996. PMID: 8627756 Free PMC article.
-
Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity.J Virol. 2011 Aug;85(16):8217-26. doi: 10.1128/JVI.00756-11. Epub 2011 Jun 8. J Virol. 2011. PMID: 21653673 Free PMC article.
-
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.J Virol. 1995 Jan;69(1):101-9. doi: 10.1128/JVI.69.1.101-109.1995. J Virol. 1995. PMID: 7527081 Free PMC article.
-
Distinct superinfection interference properties yet similar receptor utilization by cytopathic and noncytopathic feline leukemia viruses.J Virol. 1993 Sep;67(9):5153-62. doi: 10.1128/JVI.67.9.5153-5162.1993. J Virol. 1993. PMID: 8394443 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials